{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:41:36Z","timestamp":1781728896232,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T00:00:00Z","timestamp":1556755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00415-019-09349-2","type":"journal-article","created":{"date-parts":[[2019,5,2]],"date-time":"2019-05-02T17:06:47Z","timestamp":1556816807000},"page":"1879-1886","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice"],"prefix":"10.1007","volume":"266","author":[{"given":"Angela","family":"Jochim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Meindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Zwirner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Castrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,2]]},"reference":[{"key":"9349_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26817","author":"SA Norris","year":"2016","unstructured":"Norris SA, Jinnah HA, Espay AJ, Klein C, Bruggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS (2016) Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. \n                    https:\/\/doi.org\/10.1002\/mds.26817","journal-title":"Mov Disord"},{"issue":"7","key":"9349_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.25475","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK (2013) Phenomenology and classification of dystonia: a consensus update. Mov Disord 28(7):863\u2013873. \n                    https:\/\/doi.org\/10.1002\/mds.25475","journal-title":"Mov Disord"},{"key":"9349_CR3","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2147\/PPA.S141060","volume":"11","author":"B Leplow","year":"2017","unstructured":"Leplow B, Eggebrecht A, Pohl J (2017) Treatment satisfaction with botulinum toxin: a comparison between blepharospasm and cervical dystonia. Patient Prefer Adher 11:1555\u20131563. \n                    https:\/\/doi.org\/10.2147\/PPA.S141060","journal-title":"Patient Prefer Adher"},{"issue":"4","key":"9349_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/toxins5040776","volume":"5","author":"CE Gill","year":"2013","unstructured":"Gill CE, Manus ND, Pelster MW, Cook JA, Title W, Molinari AL, Charles D (2013) Continuation of long-term care for cervical dystonia at an academic movement disorders clinic. Toxins (Basel) 5(4):776\u2013783. \n                    https:\/\/doi.org\/10.3390\/toxins5040776","journal-title":"Toxins (Basel)"},{"issue":"3","key":"9349_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19(3):303\u2013308. \n                    https:\/\/doi.org\/10.1002\/mds.10659","journal-title":"Mov Disord"},{"issue":"3","key":"9349_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-1331.2004.01053.x","volume":"12","author":"IM Skogseid","year":"2005","unstructured":"Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol 12(3):163\u2013170. \n                    https:\/\/doi.org\/10.1111\/j.1468-1331.2004.01053.x","journal-title":"Eur J Neurol"},{"key":"9349_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","volume":"90","author":"J Ramirez-Castaneda","year":"2014","unstructured":"Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344\u2013348. \n                    https:\/\/doi.org\/10.1016\/j.toxicon.2014.07.009","journal-title":"Toxicon"},{"issue":"7","key":"9349_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3109\/00207454.2012.665971","volume":"122","author":"F Vivancos-Matellano","year":"2012","unstructured":"Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E (2012) A 17-year experience of abobotulinumtoxina in cervical dystonia. Int J Neurosci 122(7):354\u2013357. \n                    https:\/\/doi.org\/10.3109\/00207454.2012.665971","journal-title":"Int J Neurosci"},{"issue":"10","key":"9349_CR9","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, Group CDBS (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23(10):1353\u20131360. \n                    https:\/\/doi.org\/10.1002\/mds.22157","journal-title":"Mov Disord"},{"issue":"2","key":"9349_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s12640-017-9737-6","volume":"32","author":"AR Bentivoglio","year":"2017","unstructured":"Bentivoglio AR, Di Stasio E, Mulas D, Cerbarano ML, Ialongo T, Laurienzo A, Petracca M (2017) Long-term abobotulinumtoxin A treatment of cervical dystonia. Neurotox Res 32(2):291\u2013300. \n                    https:\/\/doi.org\/10.1007\/s12640-017-9737-6","journal-title":"Neurotox Res"},{"issue":"4","key":"9349_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265\u2013274","journal-title":"J Neurol"},{"issue":"5","key":"9349_CR12","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mdc3.12322","volume":"3","author":"H Hefter","year":"2016","unstructured":"Hefter H, Rosenthal D, Moll M (2016) High botulinum toxin-neutralizing antibody prevalence under long-term cervical dystonia treatment. Mov Disord Clin Pract 3(5):500\u2013506. \n                    https:\/\/doi.org\/10.1002\/mdc3.12322","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"9349_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1017\/cjn.2016.262","volume":"43","author":"M Jog","year":"2016","unstructured":"Jog M, Wein T, Bhogal M, Dhani S, Miller R, Ismail F, Beauchamp R, Trentin G (2016) Real-world, long-term quality of life following therapeutic OnabotulinumtoxinA treatment. Can J Neurol Sci 43(5):687\u2013696. \n                    https:\/\/doi.org\/10.1017\/cjn.2016.262","journal-title":"Can J Neurol Sci"},{"issue":"5","key":"9349_CR14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592\u2013597. \n                    https:\/\/doi.org\/10.1002\/mds.20376","journal-title":"Mov Disord"},{"issue":"2","key":"9349_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00702-014-1253-8","volume":"122","author":"D Dressler","year":"2015","unstructured":"Dressler D, Tacik P, Saberi FA (2015) Botulinum toxin therapy of cervical dystonia: duration of therapeutic effects. J Neural Transm (Vienna) 122(2):297\u2013300. \n                    https:\/\/doi.org\/10.1007\/s00702-014-1253-8","journal-title":"J Neural Transm (Vienna)"},{"issue":"8","key":"9349_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00115-008-2486-2","volume":"79","author":"T Vogt","year":"2008","unstructured":"Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 79(8):912\u2013917. \n                    https:\/\/doi.org\/10.1007\/s00115-008-2486-2","journal-title":"Nervenarzt"},{"issue":"5","key":"9349_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1179\/174313209X405137","volume":"31","author":"B Mohammadi","year":"2009","unstructured":"Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 31(5):463\u2013466. \n                    https:\/\/doi.org\/10.1179\/174313209X405137","journal-title":"Neurol Res"},{"issue":"2","key":"9349_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.parkreldis.2014.09.034","volume":"21","author":"JJ Ferreira","year":"2015","unstructured":"Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S (2015) Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism Relat Disord 21(2):111\u2013115. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.034","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"9349_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186\u20131188","journal-title":"Neurology"},{"key":"9349_CR20","unstructured":"R Core Team R (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria. \n                    https:\/\/www.R-project.org\/\n                    \n                  . Accessed 26 Dec 2018"},{"issue":"5","key":"9349_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","volume":"121","author":"H Hefter","year":"2014","unstructured":"Hefter H, Spiess C, Rosenthal D (2014) Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm (Vienna) 121(5):513\u2013519. \n                    https:\/\/doi.org\/10.1007\/s00702-013-1127-5","journal-title":"J Neural Transm (Vienna)"},{"issue":"1\u20132","key":"9349_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jns.2014.12.030","volume":"349","author":"J Jankovic","year":"2015","unstructured":"Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, Manack Adams A, Brin MF (2015) Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci 349(1\u20132):84\u201393. \n                    https:\/\/doi.org\/10.1016\/j.jns.2014.12.030","journal-title":"J Neurol Sci"},{"key":"9349_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000881","author":"VP Misra","year":"2012","unstructured":"Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, group IIC (2012) Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2012-000881","journal-title":"BMJ Open"},{"key":"9349_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.07.019","author":"M Moll","year":"2018","unstructured":"Moll M, Rosenthal D, Hefter H (2018) Quality of life in long-term botulinum toxin treatment of cervical dystonia: results of a cross sectional study. Parkinsonism Relat Disord. \n                    https:\/\/doi.org\/10.1016\/j.parkreldis.2018.07.019","journal-title":"Parkinsonism Relat Disord"},{"key":"9349_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40734-018-0072-8","volume":"5","author":"VP Misra","year":"2018","unstructured":"Misra VP, Trosch RM, Maisonobe P, Om S (2018) Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies. J Clin Mov Disord 5:4. \n                    https:\/\/doi.org\/10.1186\/s40734-018-0072-8","journal-title":"J Clin Mov Disord"},{"issue":"2","key":"9349_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3390\/toxins5020249","volume":"5","author":"J Ramirez-Castaneda","year":"2013","unstructured":"Ramirez-Castaneda J, Jankovic J (2013) Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 5(2):249\u2013266. \n                    https:\/\/doi.org\/10.3390\/toxins5020249","journal-title":"Toxins (Basel)"},{"issue":"2","key":"9349_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00702-012-0872-1","volume":"120","author":"RA Hauser","year":"2013","unstructured":"Hauser RA, Truong D, Hubble J, Coleman C, Beffy JL, Chang S, Picaut P (2013) AbobotulinumtoxinA (Dysport) dosing in cervical dystonia: an exploratory analysis of two large open-label extension studies. J Neural Transm (Vienna) 120(2):299\u2013307. \n                    https:\/\/doi.org\/10.1007\/s00702-012-0872-1","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"9349_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12640-012-9314-y","volume":"22","author":"C Colosimo","year":"2012","unstructured":"Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265\u2013273. \n                    https:\/\/doi.org\/10.1007\/s12640-012-9314-y","journal-title":"Neurotox Res"},{"issue":"8501","key":"9349_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"2","author":"JK Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2(8501):245\u2013247","journal-title":"Lancet"},{"issue":"4","key":"9349_CR30","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10072-019-3719-9","volume":"40","author":"D Ceylan","year":"2019","unstructured":"Ceylan D, Erer S, Zarifoglu M, Turkes N, Ozkaya G (2019) Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives. Neurol Sci 40(4):725\u2013731. \n                    https:\/\/doi.org\/10.1007\/s10072-019-3719-9","journal-title":"Neurol Sci"},{"issue":"7","key":"9349_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/mds.25579","volume":"28","author":"A Albanese","year":"2013","unstructured":"Albanese A, Sorbo FD, Comella C, Jinnah HA, Mink JW, Post B, Vidailhet M, Volkmann J, Warner TT, Leentjens AF, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A (2013) Dystonia rating scales: critique and recommendations. Mov Disord 28(7):874\u2013883. \n                    https:\/\/doi.org\/10.1002\/mds.25579","journal-title":"Mov Disord"},{"issue":"3","key":"9349_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00702-012-0887-7","volume":"120","author":"WH Jost","year":"2013","unstructured":"Jost WH, Hefter H, Stenner A, Reichel G (2013) Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm (Vienna) 120(3):487\u2013496. \n                    https:\/\/doi.org\/10.1007\/s00702-012-0887-7","journal-title":"J Neural Transm (Vienna)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09349-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09349-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09349-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T23:10:33Z","timestamp":1588288233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09349-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,2]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["9349"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09349-2","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,2]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A Jochim has received travel grants from Ipsen Pharma GmbH, Merz Pharmaceuticals GmbH, Pharm-Allergan GmbH, Boston Scientific, Bayer Health and Universit\u00e4tsklinikum W\u00fcrzburg as well as speaker honoraria from Pharm-Allergan GmbH. T. Meindl has received travel grants from Ipsen Pharma GmbH, Merz Pharmaceuticals GmbH, Pharm-Allergan GmbH and Boston Scientific Medizintechnik. GmbH. T. Mantel has received travel grants from Bayer Vital GmbH. S. Zwirner has no conflicts of interest. M. Zech is supported by an internal research program at Helmholtz Center Munich, Germany (\u201cPhysician Scientists for Groundbreaking Projects\u201d), has received travel expenses from Pharm-Allergan GmbH, and has received speaker honoraria from Bayer Vital GmbH. F. Castrop has no conflicts of interest. B. Haslinger has received research support from the German Research Foundation (DFG), Pharm-Allergan GmbH and Ipsen Pharma GmbH, has received speaker honoraria from Pharm-Allergan GmbH and Bayer Health Care Pharmaceuticals and has received travel grants from Ipsen Pharma GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study has been approved by the local ethics review board. All patients whose data were not only acquired retrospectively, but also recorded prospectively, gave their written informed consent before entering the prospective phase of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}